SCHEMBL15701276

SCHEMBL15701276

CCOC(=O)Cc1ccc(NC(=O)c2cscn2)cc1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.55
SMN1; SMN2 Q16637 4/20 0.55
LMNA P02545 2/20 0.55
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48
HTT P42858 1/20 0.48
GRM4 Q14833 1/20 0.46
NPC1 O15118 4/20 0.46
RAB9A P51151 4/20 0.46
TP53 P04637 2/20 0.46
POLB P06746 1/20 0.45
SIRT5 Q9NXA8 1/20 0.45
MAP3K5 Q99683 1/20 0.44
PTGDR2 Q9Y5Y4 1/20 0.44
KDM4E B2RXH2 1/20 0.44
MITF O75030 1/20 0.44
PKM P14618 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15701053 0.85 MAPT (0.44) MAPTSMN1; SMN2LMNAKMT2AMEN1
SCHEMBL15701289 0.82 KMT2A (0.63) SMN1; SMN2KMT2AMEN1GRM4TP53
SCHEMBL15070508 0.79 RAB9A (0.59) MAPTSMN1; SMN2HTTGRM4NPC1
SCHEMBL7480794 0.78 RAB9A (0.62) MAPTSMN1; SMN2LMNAKMT2AMEN1
SCHEMBL15701019 0.74 CYP2C9 (0.47) MAPTSMN1; SMN2GRM4NPC1RAB9A
SCHEMBL10685516 0.74 PPID (0.63) MAPTSMN1; SMN2LMNAKMT2AMEN1
SCHEMBL1249547 0.74 GRM4 (0.58) MAPTSMN1; SMN2LMNAKMT2AMEN1
SCHEMBL10683652 0.74 SMN1; SMN2 (0.78) MAPTSMN1; SMN2LMNAKMT2AMEN1
SCHEMBL15707505 0.74 NPC1 (0.52) MAPTSMN1; SMN2KMT2AMEN1GRM4
SCHEMBL28455181 0.74 MAPT (0.61) MAPTSMN1; SMN2LMNAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2914592-B1 INHIBITORS OF CYTOMEGALOVIRUS BOEHRINGER INGELHEIM INT (DE) 2017-10-11 EP disclosed
US-9334249-B2 Inhibitors of cytomegalovirus BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-05-10 US disclosed
US-9334249-B2 Inhibitors of cytomegalovirus BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-05-10 US disclosed
US-20150284348-A1 INHIBITORS OF CYTOMEGALOVIRUS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-10-08 US disclosed
US-20150284348-A1 INHIBITORS OF CYTOMEGALOVIRUS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-10-08 US disclosed
WO-2014070979-A1 INHIBITORS OF CYTOMEGALOVIRUS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150284348-A1 INHIBITORS OF CYTOMEGALOVIRUS CDKN1A, CCNA1, IFNAR1 MAPT 2425/4885SMN1; SMN2 4036/4885LMNA 2386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.